Actively Recruiting
Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
Led by Armed Forces Hospital, Pakistan · Updated on 2024-08-14
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.
CONDITIONS
Official Title
Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newborn babies diagnosed with moderate (grade II) or severe (grade III) hypoxic ischemic encephalopathy (HIE)
- Babies who have not received therapeutic hypothermia treatment
- Babies born indoors (in hospital)
You will not qualify if you...
- Newborns with mild (grade I) HIE
- Babies who have received therapeutic hypothermia
- Babies whose parents do not consent to participate
- Babies with major congenital malformations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MH
Rawalpindi, Pakistan, 68000
Actively Recruiting
Research Team
A
arshad Khushdil
CONTACT
A
arshad Khushdil
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here